The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

Akeso has data showing ivonescimab can extend the lives of patients with previously treated EGFR-mutated non-small cell lung ...

Inflammatory bowel disease (IBD) is a crowded drug market with plenty of treatment options across the two forms of the ...

Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

Even with Inflation Reduction Act (IRA)-related pressure looming for its top product, Teva Pharmaceuticals is continuing to ...

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

Incyte has expanded its support for projects tackling unmet needs to cover hidradenitis suppurativa (HS) patients, tightening ...

Less than three months into his tenure, Novo Nordisk’s new CEO has undeniably left his mark on the company, launching a ...

As the prospect of import tariffs and drug price reform marshals billions of biopharma investment dollars into the U.S., the ...